Experimental mRNA therapy dramatically extends treatment window for acetaminophen overdose in preclinical models

AI Summary

Researchers report that an experimental mRNA therapy substantially extended the treatment window for acetaminophen-induced liver injury in preclinical models. The finding could eventually address the narrow window for administering N-acetylcysteine, the only FDA-approved antidote for overdose-related liver injury.

When a patient arrives at the hospital with an acetaminophen overdose, it's often a race against the clock. The only FDA-approved antidote for overdose-related liver injury, N‑acetylcysteine, must be administered within hours to be effective.